The Latest Clinical Articles in Urology

1Enzalutamide: Targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerBJU International, April 01, 2015  Clinical Article
2Symptoms, unmet needs, psychological well-being and health status in prostate cancer survivors: Implications for redesigning follow-upBJU International, April 01, 2015  Clinical Article
3Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: Efficacy and safety results of the Zometa European study (ZEUS)European Urology, April 01, 2015  Full Text  Clinical Article
4PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastasesCancer Biomarkers, April 01, 2015  Clinical Article
5Magnetic resonance imaging–transectal ultrasound image-fusion biopsies accurately characterize the index tumor: Correlation with step-sectioned radical prostatectomy specimens in 135 patientsEuropean Urology, April 01, 2015  Full Text  Clinical Article
6Dose painting to treat single-lobe prostate cancer with hypofractionated high-dose radiation using targeted external beam radiation: Is it feasible?Medical Dosimetry, April 01, 2015  Clinical Article
7Comparison of field-of-view (FOV) optimized and constrained undistorted single-shot (FOCUS) with conventional DWI for the evaluation of prostate cancerClinical Imaging, April 01, 2015  Clinical Article
8Advances in robot assisted radical prostatectomyRobotic Surgery: Research and Reviews, April 01, 2015  Full Text  Review Article
9Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysisTumor Biology, April 01, 2015  Evidence Based Medicine  Review Article
10Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blotWorld Journal of Urology, April 01, 2015  Clinical Article
1UCLA researchers for the first time measure the cost of care for a common prostate conditionUCLA Health System, April 01, 2015
2Exercise linked to improved erectile and sexual function in menCedars-Sinai, April 01, 2015
3New study links urinary troubles at menopause with sleep, body fat, reaction timeThe North American Menopause Society News, March 31, 2015
4American College of Physicians joins HHS in accelerating alternative payment methods through ‘Health Care Payment Learning and Action Network’ American College of Physicians News, March 26, 2015
5Study identifies “lethal” subtype of prostate cancerUniversity of Colorado Health News, March 18, 2015

Show Me:

Chromogranin A staining as a biomarker for prostate adenocarcinoma

As reported in The Prostate, chromogranin A (CgA) staining, an indicator of neuroendocrine differentiation, is associated with decreased biochemical control, clinical failure, increased distant metastases, and decreased cause-specific survival in patients with prostate adenocarcinoma and a GS ≥ 7 (n=285). The median follow-up was 6.5 y. CgA staining was present in 31% of specimens. The 10-y distant metastases rate in specimens with <1% and >1% CgA staining was 8% and 48%, respectively. The 10-y cause-specific survival in specimens with <1% and >1% CgA staining was 95% vs. 76%, respectively.

GALNT4 predicts survival in patients with ccRCC

As reported in the Journal of Urology, N-acetylgalactosaminyltransferase 4 (GALNT4) levels are decreased in tumor specimens from patients with clear cell renal cell carcinoma (ccRCC; n=104) compared to peritumoral specimens. Decreased expression of GALNT4 is associated with poor OS (OR=3.08) and RFS (OR=2.17). Further, GALNT4 is negatively correlated with tumor size, necrosis, and TNM stage.

High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients

As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocObservation with continued ADT is recommended for asymptomatic, non-metastatic CRPC.

Clinical Pearl from Smartest DocContinuous intraoperative norepinephrine infusion decreases blood loss in patients undergoing radical cystectomy and urinary diversion.

Clinical Pearl from Smartest DocA trained canine olfactory system can detect prostate cancer-specific volatile organic compounds in urine samples.

Be Ready for Upcoming 2015 Board Exams!

Be prepared for board reviews with confidence with 1000s of board exam style questions. Prepare Here